Antigen-mediated cross-linking of Immunoglobulin E (IgE) bound to mast cells/basophils via FceRI, the high affinity IgE Fc-receptor, is a well-known trigger of allergy. In humans, but not mice, dendritic cells (DCs) also express FceRI that is constitutively occupied with IgE. In contrast to mast cells/basophils, the consequences of IgE/FceRI signals for DC function remain poorly understood. We show that humanized mice that express FceRI on DCs carry IgE like non-allergic humans and do not develop spontaneous allergies. Antigen-specific IgE/FceRI cross-linking fails to induce maturation or production of inflammatory mediators in human DCs and FceRI-humanized DCs. Furthermore, conferring expression of FceRI to DCs decreases the severity of food allergy and asthma in disease-relevant models suggesting antiinflammatory IgE/FceRI signals. Consistent with the improved clinical parameters in vivo, antigen-specific IgE/FceRI cross-linking on papain or lipopolysaccharide-stimulated DCs inhibits the production of pro-inflammatory cytokines and chemokines. Migration assays confirm that the IgE-dependent decrease in cytokine production results in diminished recruitment of mast cell progenitors; providing a mechanistic explanation for the reduced mast celldependent allergic phenotype observed in FceRI-humanized mice. Our study demonstrates a novel immune regulatory function of IgE and proposes that DC-intrinsic IgE signals serve as a feedback mechanism to restrain allergic tissue inflammation.
INTRODUCTION
Latest reports from the World Allergy Organization state that approximately 30% of the population worldwide suffers from chronic allergic diseases such as asthma or food allergy. 1 In all allergic disorders, large varieties of commonly innocuous antigens become allergens and induce detrimental immune responses. Immunoglobulin E (IgE) is well appreciated for its central role in allergy. 2 Induced by an antigen recognition event and facilitated by T-cell help, B cells start to produce antigenspecific IgE. The body's IgE pool consists of a short-lived serum IgE fraction and a cell-bound IgE fraction, which forms when monovalent IgE binds to FceRI, the high affinity IgE Fc receptor. IgE interactions with FceRI significantly prolong the half-life of the immunoglobulin and stabilize the engaged Fc receptors on the surface of mast cells and basophils. Then, minor amounts of antigen are sufficient to elicit acute allergic reactions via instant release of preformed intracellular mediators, such as histamine, from these innate effector cells. Additionally, inflammatory cytokines induced by the signaling cascade downstream of IgE/FceRI participate in the induction and dissemination of chronic allergic symptoms. 3, 4 FceRI is the multimeric immune recognition receptor that conveys the high efficiency of the antigen/IgE-mediated signals to innate IgE effector cells. On human and murine mast cells and basophils, FceRI is expressed in its classical tetrameric isoform. This isoform comprises the IgE-binding a-chain, which is associated with ITAM-bearing signaling subunits (i.e., the FceRI b-chain and the FceRI g-chain dimer). Additionally, a splice variant of the b-chain (FceRI bt) was recently described as a regulatory subunit that modulates mast cell degranulation and IL-8 production in humans. 5 Although pro-inflammatory signals downstream of tetrameric FceRI on mast cells are thoroughly studied, the functions of the second receptor isoform, trimeric FceRI, remain poorly understood. This is likely because trimeric FceRI is constitutively expressed in humans, but not in mice. This trimeric FceRI isoform, which can be found on the cell surface of human dendritic cells (DCs), lacks the FceRI-b chain and thus has one ITAM-signaling module less than the tetrameric FceRI isoform on mast cells and basophils. 3, 6 In addition to the constitutive expression on human DCs in the absence of any obvious pathology, inducible forms of trimeric FceRI have been described in allergic humans and in murine models of allergy on several cell types including monocytes, neutrophils, and inflammatory DCs. [7] [8] [9] Additionally, inducible expression of trimeric FceRI on neutrophils has been found in murine experimental cerebral malaria 10 implying that IgE signals via inducible FceRI might have functions in diseases other than allergies. How cells respond to IgEmediated signals following induction of trimeric FceRI and whether differences in the signaling of constitutively expressed and inducible receptors exist is presently unknown.
As a consequence of FceRI expression, the surface of human DCs is loaded with monomeric IgE comparable with mast cells and basophils at all times independently of the allergic status of an individual. [11] [12] [13] Importantly, this element of the human IgE pool is not reflected in murine models. As sentinel gatekeepers of innate and adaptive immunity, DCs are thought to contribute to the initiation as well as the chronicity of allergic responses. [14] [15] [16] [17] [18] [19] [20] For our understanding of immunological functions of IgE in humans, it is important to address the gaps in our understanding of how antigen/allergen-specific activation via IgE/FceRI influences key immunoregulatory functions of DCs.
DCs actively secrete inflammatory cytokines and chemokines, which impact the magnitude of the allergic tissue response directly and indirectly via the recruitment of inflammatory cells and/or their progenitors. The secretion profile of DCs during inflammation thus contributes to chronic allergies independently of their antigen presentation function. The latter mechanism equips DCs with the unique ability to activate primary T cells and induce T helper type (Th)1, Th2, Th17, and regulatory T-cell responses, 21 implying that DCs are the central antigen presenting cells for the induction of allergy. Although the detailed mechanisms still remain controversial and unclear, 14, 22 most recent evidence points to an IRF4-dependent DC subpopulation as Th2-inducing antigen presenting cells. 23 The ensuing Th2-type T cells produce signature cytokines of allergic responses, such as IL-4, IL-5, and IL-13, and are thought to initiate and perpetuate the chronicity of allergy. 24 The current hypothesis for the function of IgE-mediated antigen presentation by DCs is that FceRI-mediated antigen sampling educates the adaptive immune system to elicit Th2-type inflammation de novo. 25 This model was mainly proposed based on studies reporting higher FceRI expression on DCs from individuals suffering from atopic diseases such as allergic rhinitis, atopic dermatitis, and asthma. 8, [26] [27] [28] [29] Although these correlations argue in favor of an allergy-promoting role of IgE/ FceRI-mediated antigen presentation, they do not provide direct evidence. A recent publication demonstrated a contribution of DC-specific FceRI to serum IgE clearance; further challenging the concept that the DC-bound IgE pool is a major contributor for promoting chronic allergic inflammation. 30 During allergic responses in humans, antigen-specific IgE/FceRI signals likely influence all immune regulatory aspects of DC biology. In this study, we addressed how the DC-bound IgE pool impacts allergic responses using FceRIhumanized mice that were engineered to constitutively express a trimeric isoform of FceRI on DCs like humans while preserving expression of endogenous tetrameric FceRI on mast cells and basophils. 31 
RESULTS

FceRI-bound IgE on murine DCs does not result in the development of a spontaneous allergic phenotype in FceRIhumanized animals
The surface of humans DCs is coated with IgE bound to FceRI. [11] [12] [13] To study the consequences of IgE/FceRI-mediated DC activation for the regulation of IgE-mediated allergic responses in vivo, we capitalized on the availability of a mouse strain that is humanized for FceRI expression on DCs (referred to as IgE R -TG; 31 ). IgE is a constituent of the baseline polyclonal humoral response and is found in non-sensitized animals that are reared under specific pathogen-free (SPF) conditions. We first analyzed whether FceRI expression on murine DCs (Supplementary Figure S1 online) alters the distribution of the baseline IgE pool in SPF-housed mice. Similar to healthy nonallergic humans (Figure 1a 11, 12, 32 ), a fraction of DCs from nonsensitized IgE R -TG mice bears IgE at the cell surface (Figure 1b and c). Importantly, the FceRI-humanized mice do not display a gross-morphological allergic phenotype despite the presence of the DC-specific IgE pool. These cells are further comparable with human DCs (Figure 1a ) in that the cells with the highest FceRI expression and IgE binding capacity in the IgE R -TG animals are CD8 À DCs (Platzer et al. manuscript under review and ref. 31 ), which have been recently identified to be the homologous DC subset to human CD1c þ DCs. 33, 34 This expression profile demonstrates that IgE R -TG mice phenocopy the FceRI-and IgE-binding pattern of human DCs. In contrast to IgE R -TG DCs, DCs from wild-type (WT) mice do not carry any surface IgE (Figure 1b) . In BALB/c IgE R -TG mice, a strain with higher baseline IgE levels than C57BL/6, the DC-bound IgE fraction was readily detectable at r8 weeks, and no age-dependent increase was found (Supplementary Figure S2a) . IgE R -TG mice on the C57BL/6 background showed a significant increase in the DC-bound IgE pool with age (Supplemental Supplementary Figure S2b ). The age-dependent induction of IgG1 was comparable in IgE R -TG and WT animals (Supplementary Figure S2c ). In the absence of inflammation, serum IgE levels of IgE R -TG mice were actually reduced when compared with WT controls (Figure 1c) , likely because of a shift from the serum to the cell-bound IgE fraction. We further confirmed that comparable levels of CD23, the low affinity IgE receptor, are found on B cells in WT and IgE R -TG animals but that CD23 is not expressed on DCs (Supplementary Figure S3 ). Thus, CD23 cannot contribute to the DC-bound IgE pool at steady state in mice.
In summary, these results show that IgE R -TG mice accurately mimic the cell-bound fraction of the human IgE pool in the absence of inflammation and that FceRI-bound IgE on DCs does not induce a spontaneous allergic phenotype.
Antigen-specific IgE/FceRI cross-linking on DCs does not result in DC maturation or production of pro-inflammatory cytokines
Aiming at characterizing the consequences of IgE/FceRI-crosslinking for DC activation, we next modeled antigen-specific signals via IgE/FceRI. Splenic DCs from IgE R -TG mice were loaded with monomeric hapten-specific IgE (4-hydroxy-3nitrophenylacetyl (NP)-IgE), and haptenized antigen (NP-OVA) was used to engage surface FceRI (Figure 2a ). It has been previously described that DCs from IgE R -TG animals express the trimeric receptor as a chimera of the human a-chain and the rodent g-chains. 31 We found that cross-linking of IgE/FceRI induced rapid phosphorylation of spleen tyrosine kinase (Syk) and extracellular signal-regulated kinases (Erk1 and Erk2), which was not seen in identically treated WT DCs or after stimulation of DC with CpG DNA (Figure 2a ). These results demonstrate that the signaling cascade downstream of FceRI on DCs involves signaling molecules that also have been described downstream of the tetrameric FceRI in human and mouse mast cells. 35 After having confirmed that antigen-specific IgE/FceRIcross-linking induces a functional signaling cascade downstream of common g-chain phosphorylation in DCs, we studied phenotypic maturation and cytokine production. Humanized DCs did not responded to antigen-specific IgE/FceRI-crosslinking with upregulation of co-stimulatory molecules (Figure 2b) , indicating that IgE signals do not provide a maturation stimulus. To exclude that the lack of DC maturation was an artifact of humanized FceRI expression, we confirmed the absence of maturation signals in human monocyte-derived DCs after IgE/FceRI activation ( Figure 2c ). Analysis of culture supernatants from splenic DCs further demonstrated that neither TNF-a, IL-6, nor IL-10 were induced by IgE-mediated DC activation, although these mediators were readily detectable when DCs had been stimulated with CpG DNA or papain ( Figure 2d ). In contrast, identical IgE-mediated stimulation of mast cells from humanized FceRI mice 36 induced the production of TNF-a (Figure 2e) as described for mast cells of WT animals. 37 Microarray analysis of IgE/FceRI-activated DCs confirmed the lack of induction of TNF-a or any other inflammatory mediator on the mRNA level (Supplementary Figure S4 ). To rule out that relative changes induced downstream of IgE/FceRI were too subtle for detection by microarray, we additionally confirmed that no inflammatory cytokines are transcribed (Figure 2f and Supplementary  Table S1 ), using digital mRNA profiling with sensitivity comparable with qRT-PCR. 38 As a positive control for the functionality of the humanized DCs, we show that stimulation with CpG DNA, which is well-known to induce Th1-type . IgE R -TG DCs were also stimulated with CpG DNA, or antigen cross-linking was omitted (NT ¼ not treated). As a control, WT DCs were treated identically. Immunoblots for phospho-Syk, total Syk, phospho-Erk1/2, or total Erk1/2 are shown. (b) IgE/FceRI-cross-linking fails to upregulate the expression of maturation marker molecules in DCs from IgE R -TG mice and (c) human monocyte-derived DCs. (d) Absence of cytokine secretion by splenic DCs upon antigen-specific IgE/FceRI cross-linking. Mean of triplicates þ / À s.e.m., representative experiment (n ¼ 2); below detection level (bd) (e) TNF-a secretion from bone-marrow-derived mast cells upon antigen-specific IgE/FceRI cross-linking. (f) Absence of transcriptional responses in murine DCs after antigen-specific IgE/FceRI cross-linking. mRNA expression was determined after 8 h. OVA uptake in the presence of CpG-DNA or papain was compared with IgE/FceRI-mediated OVA uptake. Fold change compared with DCs that received OVA was calculated, and the mean of triplicates þ / À s.e.m. is shown, representative experiment (n ¼ 2). DC, dendritic cell; NP, nitrophenylacetyl; WT, wild type. immune responses, induced robust transcription of IL-12p40, TNF-a, and IL-1a, while papain induced the chemokine CCL-5 (RANTES), which is associated with Th2-type immune responses 14 (Figure 2f ). This set of experiments unequivocally demonstrates that antigen-specific IgE/FceRI signals fail to induce a proinflammatory signature in DCs.
Mice with FceRI-expressing DCs display diminished food allergic responses in vivo
To address how IgE/FceRI activation of DCs affects the severity of allergic responses in vivo, we turned to a well-characterized model of experimental food allergy that uses Th2-type sensitization with OVA/alum injections followed by repeated gavages of the model antigen to mimic physiological allergen exposure. 39 First, we confirmed that in FceRI-humanized mice DCs of the small intestine express FceRI, an expression pattern likewise found in humans ( Figure 3a and b, respectively). Comparable levels of sensitization were observed in WT and IgE R -TG animals as determined by serum levels of antigenspecific IgE and IgG1 (Figure 3c and d) arguing against a pronounced role for DC-mediated FceRI-facilitated serum IgE clearance 30 during the sensitization phase in our model. As described for allergic humans, 29 sensitization and challenge significantly increased the DC-bound IgE pool systemically in the spleen as well as locally in the mesenteric lymph nodes (Figure 3e and f, respectively). Even though OVA-specific IgE was readily detected in the serum of WT mice (Figure 3e ), no IgE was found on the DC surface in these animals (Figure 3e and f), indicating that the inducible murine form of FceRI on DCs, which was described after house dust mite (HDM) exposure and in models of viral infection, 22, 40 was not present in this model. IgE-mediated food allergy presents with extensive Th2-type tissue inflammation in the small intestine, and intestinal mucosal mast cell numbers are an established quantitative measure of disease severity in mice and humans. 39 Comparative quantitative mRNA profiling was performed to assess the extent of tissue inflammation in the small intestine of food allergic animals. We found that the lamina propria of IgE R -TG animals was overall substantially less inflamed ( Figure 4a and Supplementary Table S2 ). mRNA transcripts of mast cell-specific proteases (MCPT-1 and MCPT-2, and carboxypeptidase A3), Th2-type cytokines (IL-4 and IL-13), and DC-derived inflammatory mediators such as CCL-2 and IL-6 were significantly less abundant in the tissue of IgE R -TGs than in WT controls ( Figure 4a ). Expression of IFN-g was low and did not change upon challenge (Supplementary Figure S5a ). Additionally, significantly lower transcript levels of the Th2-specific cytokines IL-33 and IL-13 were found in the mesenteric lymph nodes of IgE R -TGs. In contrast, transcript levels of IL-2 and IL-12p40 and were comparable in both strains demonstrating a specific inhibition of cytokines associated with mucosal Th2 immune responses (Supplementary Figure S5b ). We did not detect significant changes between challenged WT and IgE R -TG animals in regard to percentages of Foxp3 þ CD25 þ T cells in the mesenteric lymph nodes (Supplementary Figure S5c ). Furthermore, IL-10 production was similar (Supplementary Figure S5d ), suggesting that the regulatory T-cell compartment was not responsible for the restrained tissue inflammation in the IgE R -TG mice.
Chloroacetate esterase staining for mucosal mast cells on intestinal tissue sections confirmed that mast cell numbers were likewise profoundly decreased in antigen-challenged IgE R -TG animals (Figure 4b and c). To assess IgE-dependent mast cell activation systemically, 41 we quantified serum MCPT-1 levels 1 h after antigen challenge. MCPT-1 was readily detectable after oral challenge and MCPT-1 levels in IgE R -TG mice were significantly lower compared with WT animals (Figure 4d ), demonstrating that systemic consequences of IgE-mediated mast cell activation are also dampened in FceRI-humanized mice. These data demonstrate that DC-bound IgE pool has an inhibitory function that reduces mucosal inflammation as well as systemic responses during food allergy. This effect was only seen after oral challenge. When mice were systemically challenged intravenously, similar amounts of MCPT-1 were found in the serum of both strains (Supplementary Figure S5e ). This finding further argues against enhanced IgE clearance as a mechanism of mitigated allergic inflammation in IgE R -TG animals and suggests a tissue-specific antiinflammatory function of DC-bound IgE.
Chronic asthmatic inflammation is diminished in mice with FceRI-expressing DCs
We next aimed at analyzing whether the dampening of inflammation by the DC-specific IgE pool is a general regulatory principle for allergic responses or is, alternatively, specific for intestinal allergies. We here decided to study allergic asthma as the most common allergic disease worldwide. 1 An earlier observation from our collaborators demonstrated an exacerbation of airway inflammation in FceRI-humanized animals. 31 Therefore, it was also important to revisit the effects of the DC-bound IgE pool on allergic asthma. Because our current study found a pronounced effect on the mast-celldependent IgE-effector axis, we chose a chronic asthma model, which induces the disease by repeated intranasal antigen exposure without systemic sensitization. This model is currently considered closest to the induction of human asthma and is also characterized by increased tissue mast cell numbers. 42, 43 First, we confirmed that, in contrast to CD11c þ DCs, CD11c þ macrophages in the lung do not express FceRI or bind IgE (data not shown 31 ). Applying this model, we found that IgE R -TG mice exhibited less severe disease symptoms based on measurements of airway resistance (Figure 5a) . Consistent with the food allergy model, a significant decrease in mast-cell/ basophil-specific mRNA transcripts was detected in the lung (Figure 5b) . Importantly, the protective features of the DCbound IgE were also apparent at the cytokine/chemokine level. Transcripts of proinflammatory cytokines CCL-2, TNF-a, and IL-6 were overall decreased in lung tissue of IgE R -TG mice Figure S6c) . These data suggest that IgE/FceRI-mediated DC activation predominantly affects mast-cell-associated inflammation and might not affect eosinophils. Thus, our results are not necessarily contradicting the study of Sallman et al. 31 which focused on a model that mimics the early eosinophil-dependent phase of allergic asthma but not the chronic allergic lung inflammation, which involves mast cells. Importantly, our results show improvement of a clinical parameter of another chronic allergic disease in IgE R -TG mice.
We next studied HDM-induced allergic airway inflammation to address whether high protease content of antigens combined with pattern recognition receptor activation can overcome the immune regulatory effect of the DC-bound IgE pool. Unlike the food allergy model and the chronic airway inflammation model induced with OVA, the allergic pathology in the HDM model is not predominantly driven by mast cells. 44 As described for the HDM model, we observed more pronounced eosinophil infiltration than in the OVA sensitization model. Comparable with the OVA model, no significant difference of eosinophil infiltration in bronchoalveolar lavage fluid or lung tissue was found in WT and IgE R -TG mice (Supplementary Figure S7a) . No significant infiltration of mast cells was detected in the HDM model, however, we found a trend for lower expression of CCL-2, IL-6, and TNF-a (Supplementary Figure S7b and S7c). Although tissue expression levels of IL-4, IL-13, and IL-5 were not lower in the lungs of IgE R -TG mice, the CD4 þ T cells expressed significantly less IL-13 receptor (Supplementary Figure S7d and S7e). Importantly, a significant reduction of IL-33 was found (Supplementary Figure S7f) , which is indicative for ameliorated lung inflammation in the IgE R -TG mice. This set of experiments confirms in a third independent model of allergy that the production of pro-inflammatory Th2-type cytokines is not enhanced in IgE R -TG mice and further demonstrates that even in the presence of strong protease and pattern recognition receptor signals, allergic Th2-type inflammation is not amplified by the DC-bound IgE pool. Interestingly, the anti-inflammatory effects of the DC-bound IgE pool were more pronounced in models of allergy that depended heavily on mast cell infiltration for disease severity.
The DC-specific IgE pool restrains food allergy in mice that lack FceRI expression on mast cells and basophils
To further study the immune regulatory features of IgE/FceRImediated DC activation, we generated mice that lack expression of FceRI on mast cells and basophils and express the IgE receptor only on DCs (IgE R -TG x mu a -KO, Figure 6a ). DCs from IgE R -TG x mu a -KO mice were more densely loaded with IgE than cells from their parental humanized strain (Figure 6b) , and OVA-specific serum IgE after challenge was significantly higher compared with IgE R -TG and WT animals ( Figure 6c) . Notably, in mice that completely lack murine FceRI (mu a -KO), IgG1-mediated immune activation compensates for the lack of IgE-derived inflammatory signals, and mu a -KO animals display all common signs of allergic inflammation. 45 In line with this previous report, we found a severe allergic response in mu a -KO and WT animals as determined by a profound increase of intestinal mast cell transcripts ( Figure 6d ). In contrast, IgE R -TG x mu a -KO mice displayed a significantly less severe allergic phenotype that was comparable with IgE R -TG animals ( Figure 6d ). This data set confirms that the immune regulatory function of IgE is uniquely executed by the cell-bound DC-specific IgE fraction and does not involve IgE-mediated crosstalk with mast cells. Furthermore, the experiments show that DC-specific IgE signals restrain the allergic response beyond the inflammation that results from IgE-dependent mast cell and basophil activation.
IgE-mediated antigen presentation does not promote generation of Th2-type effector T cells
The inhibitory activity of IgE/FceRI-bearing DCs described above is in potential disagreement with the Th2-promoting function of IgE/FceRI-mediated antigen presentation noted previously. 31, 46 We therefore revisited the role of the IgE presentation pathway in T-cell proliferation and Th2-type T-cell priming. First, we confirmed the extraordinary sensitivity of this antigen presentation pathway 31, 47 with DCs from IgE R -TG animals. We isolated splenic DCs, pre-loaded them with NP-IgE and pulsed with NP-OVA for 1 h. We then injected these DCs into WT recipient mice to assess the induction of T-cell proliferation in vivo. Analysis of the draining lymph nodes revealed that only IgE-loaded DCs induced a strong proliferative response of adoptively transferred CFSE-labeled OVA-specific T cells in the low antigen concentration range (Figure 7a , second antigen concentration: Supplementary Figure S8a ). In contrast to the Th2-promoting stimulus papain, 14, 48 IgE/FceRI mediated-antigen uptake by DCs failed to induce an inflammatory Th2 profile in CD4 þ T cells in vivo (Supplementary Figure S8b) . To rule out that the Th2 response was simply under the detection limit in this assay, we confirmed these data with in vitro antigen presentation assays. Here, we altered the antigen loading conditions to allow for a more physiological setting. In contrast to previous studies where DCs were pulsed with antigen in the cold, our loading conditions allowed for IgE-dependent and IgE-independent antigen uptake in parallel over prolonged periods of time at 371C. As noted previously, when IgE-loaded DCs from IgE R -TG animals were used, T-cell proliferation was induced in a low antigen concentration range that otherwise failed to initiate T-cell responses. Titration experiments over a broader antigen concentration range demonstrated that IgE/FceRI-mediated antigen uptake by DCs increased T-cell proliferation most effectively at low concentrations (r0.5 mg/ml), whereas no significant impact on the proliferative responses was observed at higher concentrations (Figure 7c ). In line with previously published data, 31 day 3 supernatants of the DC/T-cell cocultures contained more IL-4 and IL-13 when IgE/FceRImediated uptake was used for antigen sampling (Figure 7d ). However, antigen titration experiments showed that this early IL-4 production by T cells was a response to increased antigen uptake by the DCs at a low antigen concentration rather than a specific consequence of IgE/FceRI signaling (Figure 7e) . At the higher antigen concentration, we actually observed less IL-4 after IgE/FceRI-mediated uptake when compared with fluid phase uptake (Figure 7e ). Because priming of naïve T cells into fully differentiated T effector cells requires more than 3-4 days, we next analyzed the effector T-cell phenotype at day 7 by staining for intracellular cytokines. Notably, T cells that were induced after IgE-mediated antigen presentation failed to differentiate into IL-4 þ Th2 cells (Figure 7f ). Because in vivo basophils and innate lymphoid cells have been demonstrated to provide additional IL-4, which is essential for Th2 cell priming via DCs, 48 we added recombinant IL-4 to the DC/T-cell cocultures. Importantly, even in the presence of exogenous IL-4, IgE/FceRI-mediated antigen presentation failed to generate more efficient Th2 effector responses than seen in the controls (Figure 7e and Supplementary Figure S8c ). Addition of lipopolysaccharide (LPS) to the DC/T-cell cocultures results in a Th1-type response as evident by the presence of a high percentage of IFN-g þ T cells (Figure 7f) . IgE/FceRI-mediated antigen presentation did not diminish the induction of Th1 cells by LPS and rather reduced the numbers of IL-4 þ T cells in LPS cultures (Figure 7f and Supplementary Figure S8c ). To test if increased antigen uptake through IgE/FceRI can promote Th1 responses, we added IL-12 or CpG DNA to the DC/T-cell cocultures. We detected more IFN-g þ T cells in the presence of IL-12 and IgE (Figure 7g ). Similar to IL-12, we found more IFN-g and less IL-13 production in the presence of CpG DNA and IgE (Supplementary Figure S8d) . These data suggest that IgE/FceRI-mediated antigen uptake can, in fact, increase Th1 immune responses when the DCs receive Th1-supporting stimuli during antigen presentation. We also tested whether IgE/FceRI-mediated antigen uptake could promote the priming of inducible regulatory T cells (iTreg). Addition of TGF-b1 to DC/T-cell cocultures resulted in the de novo generation of CD25 þ Foxp3 þ iTregs and IL-10-expressing CD4 þ T cells from purified naïve CD25 À OT-II T cells. No significant difference in iTreg priming or IL-10 þ CD4 þ T cells was detectable in the presence or absence of IgE-mediated antigen uptake through DCs ( Supplementary Figure S8e and S8f) .
In conclusion, we confirmed that IgE-mediated antigen presentation enables DCs to initiate T-cell proliferation in response to extraordinarily low doses of soluble antigen. The ensuing T cells, however, failed to fully differentiate into a Th2 effector type. This result is in line with our in vivo experiments in IgE R -TGs mice, where no evidence of increased Th2-type T-cell responses was detected (Figure 4a ; Supplementary  Figures S5b and S7d) .
Cross-linking of IgE/FceRI inhibits production of proinflammatory mediators from activated DCs and thereby interferes with recruitment of mast cell progenitors
So far, we showed that antigen-specific IgE/FceRI-cross-linking does not induce phenotypic DC maturation, that the DC-specific IgE pool does not promote Th2-type inflammation in vivo, and that IgE-mediated antigen presentation fails to efficiently induce Th2 effector cells. In summary, these findings imply an immune regulatory function of DC-specific IgE signals. We next turned our attention to identifying the cellular basis of the inhibitory function of IgE/FceRI-mediated DC activation observed in the in vivo studies describe above. To this end, we determined the responses of DCs stimulated with papain and low dose LPS, i.e., stimuli that mimic DC activation occurring during allergic responses in vitro and then measured the cytokine response to such stimulation. 48, 49 On the basis of the suppression of cytokine patterns in our in vivo experiments (Figures 4 and 5) , we selected CCL-2, IL-6, and TNF-a as likely candidates for being subjected to regulatory IgE signals in activated DCs. In vitro stimulation with papain strongly induced CCL-2, IL-6, and TNF-a production by DCs (Figure 8a) . Importantly, in the presence of antigen-specific IgE/FceRI signals, significantly lower amounts of all three inflammatory mediators were detected (Figure 8a) . IgE/FceRI cross-linking also inhibited inflammatory cytokine production in response to low dose LPS (Supplementary Figure S9a) . We detected no significant difference whether FceRI cross-linking occurred simultaneously or consecutively to LPS stimulation. In a time course experiment, we saw that the inhibitory effect of IgE activation on inflammatory cytokine production was not detectable after 6 h, already measurable after 24 h, but most evident after 48 h (Supplementary Figure S9b) . This experiment indicates that IgE-derived inhibitory signals are cumulative over time as evident by the strongest inhibition at later time points.
To further investigate the different outcomes on cytokine production in mast cells and DCs, we compared side-by-side the signaling cascades after IgE/FceRI cross-linking (Supplementary Figure S9c ). We found similar levels of total ERK1/2 in both cell types, but stronger ERK1/2 phosphorylation upon IgE/FceRI cross-linking was observed in mast cells compared with DCs. No inhibition of ERK1/2 phosphorylation upon IgE/ FceRI cross-linking in the presence of LPS was detected in the DCs (Supplementary Figure S9d) . When analyzing Scr homo-logy2 domain-containing phosphatase (SHP)-1 and SHIP-1, two phosphatases that have been described to regulate ITAM signaling, we found higher expression of both proteins in DCs compared with mast cells (Supplementary Figure S9c) . We did not detect an increase in phosphorylation of SHIP-1 in DCs upon receptor cross-linking with 0.5 mg/ml OVA, the concentration commonly used in our experiments. Because SHP-1dependent inhibitory ITAM signal has been demonstrated for FcgRIII, 50 we also tested whether FceRI cross-linking in the presence of LPS would lead to SHP-1 phosphorylation. We did not detect an increase in pSHP-1 (Supplementary Figure S9d) . Thus, the pathway operative downstream of trimeric FceRI in DCs seems different from those described so far for mast cells and other inhibitory Fc receptors.
We next validated the presence of inhibitory IgE-mediated signals for its relevance to humans by demonstrating that activated human DCs also produce significantly lower amounts of CCL-2 upon IgE-mediated activation (Figure 8b) . High donor variability with regards to responses to papain stimulation was found in humans. Papain-responsive DCs showed the same inhibitory pattern of CCL-2 production upon antigenspecific IgE cross-linking as LPS-stimulated cells (Figure 8b) . This set of experiments demonstrates that antigen-specific IgE/FceRI-cross-linking on activated DCs reduces, rather than promotes, the production of pro-inflammatory mediators. Because human DCs show the same restrained cytokine/ chemokine release after IgE/FceRI activation, we provide evidence that our findings directly translate to human DC function.
CCL-2, also known as monocyte chemotactic protein 1 (MCP-1), attracted our attention particularly because it exhibits strong chemotactic activity for CD117 þ (KIT þ ) mast cell progenitor cells and DCs, in addition to its function in the recruitment of monocytes and T cells to sites of inflammation. [51] [52] [53] [54] Because repeated antigen challenges increase allergic tissue inflammation over time through the influx of inflammatory progenitor cells, we hypothesized that inhibition of CCL-2 production by antigen-specific IgE signals should impair trafficking of mast cell progenitors. To test this hypothesis, we first confirmed the chemotactic properties of CCL-2 for murine mast cell progenitors and CD11c þ DCs (Figure 8c ). Next, we performed chemotaxis assays using conditioned supernatants from IgE-preloaded DCs, which we activated with papain or LPS in the presence or absence of antigen-mediated cross-linking. Papain and LPS activation induced the production of cell supernatants with strong chemotactic activity for mast cell progenitors as well as CD11c þ DCs (Supplementary Figure  S10) . In line with our hypothesis, we found that migration of mast cell progenitors and CD11c þ DCs from bone marrow progenitor cultures was reduced in average by over 30% to 50%, respectively, when supernatants from IgE/FceRIactivated DCs were used (Figure 8d) . Antigen-specific IgE/FceRI-cross-linking, however, did not interfere with LPS-induced upregulation of co-stimulatory molecules, such as CD86, by neither mouse nor human DCs (Supplementary Figure S11 and data not shown).
In summary, these experiments demonstrate that IgE-mediated signals interfere with the production of inflammatory, Th2-promoting mediators by activated DCs. In an allergic setting in vivo, inhibited production of these mediators explains why the allergic tissue is overall less inflamed in IgE R -TG mice (see model, Supplementary Figure S12) . Additionally, the decreased production of the mast-cell-tropic chemokine CCL-2 implies that the dampening of the IgE-effector cell axis is due to the diminished inflammatory progenitor cell recruitment to sites of allergic tissue inflammation.
DISCUSSION
This study on the functions of DC-bound IgE reveals to our knowledge an unidentified immune regulatory mechanism mediated by antigen-specific cross-linking of IgE/FceRI on DCs. We found that IgE R -TG animals, which mimic the constitutive IgE receptor expression pattern of humans and therefore bind IgE at the cell surface of DCs, suffer from significantly less severe clinical symptoms of allergies than WT animals. This protective feature of IgE-mediated immune activation was likely not detected to date because the DCspecific IgE pool is not found in laboratory WT mice. Our study thus adds allergic Th2-type diseases to the list of human conditions that are not fully modeled by the murine immune system in their entire complexity. 55 Comparable sensitization levels were detected in FceRIhumanized and WT mice arguing against a redistribution of the available IgE pool from serum to the DC-bound fraction as a simple explanation for impeded allergic tissue responses. Additionally, the availability of similar amounts of antigenspecific IgE for mast cell activation was confirmed by demonstrating that mast cell degranulation after systemic antigen exposure is similar in IgE R -TG and WT mice. Our findings do not exclude that FceRI on DCs also contributes to serum IgE clearance as described recently. 56 We show, however, that DC-bound IgE has an additional active role in regulating mucosal allergic responses on the tissue level.
A mechanistic explanation for the observation that the DCbound IgE pool executes regulatory rather than pro-allergic signals derives from our demonstration that IgE/FceRI cross-linking on activated DCs inhibits the production of allergy-promoting inflammatory cytokines. Furthermore, the decreased generation of chemokines indicates that lower mast cell numbers in allergic tissues of IgE R -TG animals result from less efficient recruitment of inflammatory cells to the affected tissue. Our experiments clearly identify CCL-2 as one of the key chemokines that regulates trafficking of mast cell precursors under the direct control of DC-specific IgE signals. The observation that decreased levels of CCL-2 result in ameliorated allergy is also supported by the literature, demonstrating that CCL-2 serves as an amplifier of pro-inflammatory effector functions of mast cells and basophils during allergic airway inflammation. [57] [58] [59] [60] The anti-inflammatory role of IgE-mediated DC activation directly opposes the pro-inflammatory role of IgE/FceRI on mast cells/basophils. How can these obviously cell-type-specific outcomes be explained? Although the signaling cascade in DCs appears comparable with the one induced in mast cells by IgE/ FceRI cross-linking, the lack of the signal-amplifying b-chain in the DC-specific trimeric FceRI isoform is an obvious difference between the two cell types. Thus, differences in signal strength and/or activation of alternative signaling cascades might explain the divergent functional outcomes. Importantly, our finding that Syk phosphorylation via IgE/FceRI cross-linking in DCs inhibits cytokine production is not the first demonstration of an inhibitory signal by this kinase. Distinct immunoregulatory roles for Syk signaling through several types of ITAMassociated receptors have been described, including CD89 (the high affinity IgA Fc receptor), b2-integrins, NKp44, Siglec-H, immunoglobulin-like transcript 7 (ILT7), and CD303. [61] [62] [63] [64] [65] [66] [67] For example, Syk activation downstream of the integrin CD11b has been shown to inhibit inflammatory responses triggered by TLR signaling in innate immune responses. 67, 68 Additionally, it has been demonstrated that Syk signaling can fine-tune innate immune responses to lessen inflammation. 69 Mechanistically, the inhibitory signals mediated by the diverse receptors have been demonstrated to include indirect ITAM cross-regulatory mechanisms, ITAM-mediated sequestration of effector molecules as well as recruitment of inhibitory effectors, like SHP-1. 61, 70 Because the IgE/FceRI interaction is of a very high affinity and we cross-linked the receptor with haptenized antigen, we speculate that the inhibitory mechanism of IgE/ FceRI signaling in DCs probably differs from the inhibitory signals induced by the monomeric low-avidity ligation of CD89 by IgA, which functions through recruitment of SHP-1. 66, 71 How Syk activation after IgE/FceRI cross-linking exactly interferes with DC activation and results in the downregulation of cytokine production will be an important question to address in the future.
We further demonstrated that antigen presentation via the DC-bound IgE pool does not promote expansion of Th2-type effector T cells. Thus, our data suggest that this pathway of antigen recognition does not fuel the Th2-perpetuating immune machinery in allergy. Our findings are in line with several epidemiologic observations, which also challenge the previous interpretation that IgE/FceRI signals provide DCs with Th2-promoting stimuli. First, although human DCs are preloaded with IgE independent of the age or the allergic status of an individual, not every human develops allergy. Secondly, although IgE/FceRI expression on DCs appears to correlate with serum IgE, 29 high IgE levels are frequently found in the absence of an allergic phenotype. 11, 12, 32 It is important to discuss why IgE/FceRI-mediated antigen presentation by DCs has traditionally been believed to foster generation of allergic T-cell responses. The IgE-mediated presentation pathway was originally described with birchpollen-specific T-cell clones and HLA-matched DCs from allergic donors. 6, 47 The use of established human T-cell clones is a shortcoming in this setting because obtained data do not allow for conclusions with regards to priming of naïve T cells or their differentiation towards specific T effector cells. Only the availability of DCs from FceRI-humanized mice, which can be analyzed in combination with primary antigen-specific T cells, allows for an evaluation of the IgE/FceRI presentation pathway for the generation of Th2 effector cells. The intracellular cytokine staining of T cells generated with this strategy in our study demonstrated convincingly that the IgE/FceRI pathway is not superior in its ability to induce Th2-type effector T cells. However, we confirmed earlier observations that IgE/FceRImediated antigen uptake induces T-cell proliferation to otherwise sub-stimulatory antigen concentrations. 31, 47 With regard to this question, in contrast to previous studies where the antigen binding to IgE/FceRI of was performed at 4 1C to restrict fluid phase antigen uptake, 6,31 our experimental conditions of continuous antigen availability at 37 1C allowed for the first straightforward comparison of IgE-dependent and independent uptake pathways. Thus, these experiments better replicate the in vivo situation where DCs use multiple antigen sampling pathways simultaneously. We cannot formally exclude that the increased T-cell proliferation and early IL-4 production initiated through IgE-mediated antigen uptake may contribute to Th2 responses under certain circumstances. However, the in-depth characterization of IgE/FceRI-mediated antigen presentation by DCs as presented in our study ranks this event very low as a causative candidate for initiating allergen-specific Th2 cells.
Targeting FceRI on DCs with antigen-IgE fusion proteins was recently demonstrated as a pathway to induce antigenspecific T-cell tolerance in FceRI-humanized mice. 72 It is important to stress that the major difference of this study to ours was the use of monomeric IgE fused with antigen. Such an IgE fusion binds to FceRI but does not allow for cross-linking as seen with antigen in vivo. The intracellular pathway used by monomerically engaged FceRI is unlikely to be operative in our models where internalization is induced by multimeric ligation. Irrespectively, targeting an FceRI-mediated antigen uptake pathway to specifically induce T-cell deletion is an interesting approach to make use of non-inflammatory IgE-mediated antigen presentation events.
At first glance, the immunoprotective characteristics of the DC-specific IgE pool stand in contrast to a previous report that demonstrated exacerbation of early eosinophil-dependent airway inflammation in IgE R -TGs mice. 31 Note that the study of Sallman et al. 31 used a different, less physiological sensitization approach than we did in our asthma models. Additionally, this study did not evaluate airway resistance as a clinical parameter of allergic asthma. Even though our experiments support the protective nature of DC-specific IgE in allergic lungs by additionally demonstrating an overall decrease in inflammatory cytokines/chemokines and the absence of increased eosinophil numbers, our data do not formally exclude that early eosinophil-dependent inflammation is enhanced in the humanized animals. Irrespectively, we demonstrate that the consequences of DC-intrinsic IgE signals for chronic allergic inflammation are an improved clinical phenotype and not more severe asthma symptoms. We also argue that the immunoregulatory mechanism of IgE is supported by the description of an inducible form of FceRI on murine inflammatory DCs in the lung. 22, 40 The authors originally interpreted the induction of FceRI on DCs as a mechanism to promote allergic inflammation. At the time of these studies, such interpretations were the most plausible based on the current paradigms of IgE-mediated immune activation. On the basis of our findings, we propose as an alternative explanation that FceRI is induced in mice as part of a counter-regulatory mechanism aimed at dampening allergic inflammation. The relevance of this new interpretation for human allergy is supported by our finding that human monocyte-derived DCs, which are generally considered to be an inflammation-associated DC subset, show the same immunesuppressive pathways of IgE-mediated cell activation.
However, during the development of human allergy, regulatory signals from the DC-bound IgE pool are obviously not sufficient to prevent or resolve overshooting inflammatory Th2-type response. It is here important to keep in mind that the consequences of IgE-triggering via constitutively expressed FceRI on DCs cannot automatically be translated to functions of the inducible form of trimeric FceRI on innate cells such as neutrophils or monocytes as described in allergic humans. 7, 11 It is conceivable that IgE signals via inducible trimeric FceRI contribute to the exacerbation of allergy.
We propose that IgE-mediated DC activation acts as a checkpoint and serves as an inhibitory feedback mechanism to downregulate inflammation during allergic responses. It is important to keep in mind that overshooting inflammatory Th2-type immune responses are not only seen in allergy, but can also occur during encounters with helminth parasites. 73 Among the detrimental consequences of the failure to restrain Th2 responses is tissue fibrosis. 74 The existence of a counterregulatory feedback mechanism that controls the magnitude of these immune responses via antigen-specific IgE seems thus highly beneficial and evolutionarily justified.
In summary, we suggest that re-examining our view of IgE is warranted because the anti-inflammatory DC-specific functions demonstrated here challenge the current notion of this immunoglobulin as a dominantly pro-inflammatory mediator.
Additionally, our findings may have the potential to serve as the basis for novel therapeutic strategies for the treatment of allergy by exploiting the DC-based immunoregulatory features of IgE.
METHODS
Mice. All animals were bred under SPF conditions at Boston Children's Hospital (Boston, MA). In vivo experiments were performed in littermate-controlled settings. Age-matched WT mice that had been co-housed after weaning were used in addition to littermates. OT-II TCR transgenic animals were purchased from The Jackson Laboratory (Bar Harbor, ME). All animal studies were approved by the Boston Children's Hospital or the Brigham and Women's Hospital Institutional Animal Care and Use Committees.
Antibodies and reagents. Hapten-specific chimeric human IgE anti-NP was derived from Jw 8/5/13 cells (clone JW8/1, AbD Serotech, Raleigh, NC). NP(7)-PE and NP-OVA (B19 NP-moieties per OVA) were purchased from Biosearch Technologies (Petaluma, CA). NP-OVA was size-purified (10 kDa4NP-OVAo100 kDa) to remove OVA peptide and higher MW OVA aggregates in the soluble antigen solution with Amicon Ultra Ultracel 10k and 100k centrifugal filters (EMD Millipore, Billerica, MA). Measurement of immunoglobulins. Serum levels of total and OVA-specific IgE and IgG1 were determined by ELISA. Total IgG1 was determined using the mouse IgG1 ELISA Ready-SET-Go! from eBioscience. For total IgE, 96-well plates were coated overnight at 4 1C with goat isotype-specific antibodies to IgE (1110-01, Southern Biotech) diluted 1:1000 in coating buffer (eBioscience). After six washes with 0.05% Tween 20 (Sigma Aldrich) in phosphate-buffered saline, plates were blocked with 2% (w/v) bovine serum albumin (Sigma Aldrich) in phosphate-buffered saline (Life Technologies, Grand Island, NY) for 4 h. Serum samples were diluted 25-200 fold and incubated overnight at 41C. HRP-conjugated anti-mouse IgE (1110-05, Southern Biotech, Birmingham, AL) was added for 1 h prior to development with tetramethylenbenzidine (KPL, Gaithersburg, MD). After addition of 2 M H 2 SO 4 , spectrophotometric analysis at 450 nm (Spectramax 250, Molecular Devices, Sunnyvale, CA) was obtained and serum Ig concentrations were calculated from a standard curve with a commercially available IgE antibody (557079, BD Pharmingen). For OVA-specific IgE and IgG1 the above-described protocol was adjusted as follows: Plates were coated with goat a-mouse IgE (d1:1000, Southern Biotech) or goat anti-mouse IgG1 (Southern Biotech), respectively. For the standard curves mouse anti-OVA specific IgE (AbD Serotech) or mouse anti-OVA IgG1 (Sigma Aldrich) were used. Detection was performed by incubating with biotinylated OVA (1 mg/ ml) for 1 h, followed by Streptavidin-HRP (BD Pharmingen) for 30 min.
Measurement of cytokine production. Cytokine production was determined using commercially available Ready SET Go ELISAs! (eBioscience) or was assessed using the BD Cytometric Bead Array and analyzed using FCAP Array Software v1.0.1 (BD Bioscience).
In vitro stimulation of murine DCs. Bone-marrow-derived or splenic DCs were stimulated with 25 mg/ml papain (Calbiochem, Billerica, MA), 500 ng/ml CpG DNA (ODN 1668), and/or NP-OVA (0.5 mg/ml) in the presence or absence of NP-specific IgE.
Cell culture and generation of bone-marrow-derived DC. DCs were cultured in RPMI-1640, 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. T-cell cultures were supplemented with 55 mM b-mercaptoethanol. Bone marrow was collected and cultured as described. 75, 76 For generation of DCs, bone marrow cells were cultured at 1.5 Â 10 6 cells/ml with 200 ng/ml human Flt3-ligand (Peprotech, Rocky Hill, NJ) for 8-10 days.
Human monocyte-derived DCs. Monocytes were isolated from healthy blood donors (IRB approved and provided by the Kraft Family Blood Donor Center of the Dana-Farber Cancer Institute and Brigham and Women's Hospital) using the MACS CD14 þ positive selection kit (Miltenyi Biotec). Cells were cultured with recombinant human GM-CSF (1000 U/ml) and IL-4 (500 U/ml) for 5 days. FceRI expression was confirmed by FACS. To obtain highly pure DC populations, CD1a þ cells preloaded with NPspecific IgE were purified using MACS microbeads (Miltenyi Biotec). A total of 5 Â 10 5 DCs were cultured in 1 ml RPMI in 48-well plates. DCs were activated as indicated with 0.05 mg/ml NP-OVA, 100 ng/ml LPS, or 25 mg/ml papain. NP-OVA was added 5-10 min prior to LPS or papain. Cells and culture supernatants were collected after 16 h. CCL-2 was measured using the human CCL-2 Ready SET Go ELISAs! (eBioscience).
Food allergy model. Intestinal allergic reactions were induced as previously described (Ahrens et al. 39 ). Briefly, mice were sensitized with 100 mg of OVA (grade V, Sigma Aldrich) in a 1:1 alum adjuvant suspension (Imject Alum Adjuvant, Thermo Scientific, Waltham, MA) by intraperitonial (i.p.) injection on days 0 and 14. Control mice received alum alone. Briefly, commencing on day 28, all mice were challenged with 50 mg of OVA on alternating days for a total of three to six administrations. Mice were deprived of food for 3 h prior to each challenge. Tissue was harvested 24 h after the last challenge. Intestinal mast cell quantification jejunum tissue was collected 10-12 cm distal to the stomach and processed by standard histological techniques. Tissue sections were stained for mucosal mast cells with chloroacetate esterase activity. 77 Fifteen high power fields of tissue from three IgE R -TG and three WT mice were counted by two blinded investigators.
Asthma model. Mice were sensitized to OVA by repeated intranasal applications three times a week for a total of 10 applications as previously described (Williams and Galli 42 ; Yu et al. 43 ). Sensitization was confirmed by the presence of OVA-specific IgE in serum. Mice were subjected to analysis 24 h after the last OVA application. Measurement of airway resistance: Methacholine challenge test: Mice were anesthetized with sodium pentobarbital (100 mg/kg, i.p., Oak Pharmaceuticals, Raleigh, NC), tracheotomized, and connected to the Flexivent rodent ventilator (Scireq Montreal, QC, Canada) via a tracheal cannula. Methacholine (Sigma-Aldrich) was aerosolized trough the inhalation port for 10 s, and the airway resistance (Rn) was measured at a positive end-expiratory pressure of 2.5 cm H2O, as described. 78 For unprovoked lung physiology studies, mice were anesthetized and connected to the Flexivent ventilator as above. After unprovoked lung physiology studies, lungs were lavaged trough the tracheal cannula to collect bronchoalveolar lavage fluid. Total cells in the BAL were determined; neutrophils and eosinophil numbers were obtained after staining a cytospin with Hema 3 Staining kit (Fisher Scientific, Hampton, NH). For the collection of lung tissue, mice were exsanguinated through right ventricular puncture and pulmonary circulation was perfused via the right ventricle.
For HDM-induced airway inflammation, mice were sensitized once intranasal with 5 mg HDM extract (Greer Labs, Lenoir, NC) per mouse. Commencing 1 week after the initial sensitization, mice were challenged with 25 mg HDM per mouse, three times a week for a total of eight intranasal applications. Single cell suspensions of lung tissue for flow cytometric analysis were prepared using the Lung Dissociation Kit from Miltenyi Biotec.
Chemotaxis assay with mast cell progenitors. DCs were activated with papain or LPS in the presence or absence of antigen-specific IgE/FceRI cross-linking (NP-OVA was added 5 min prior to LPS or papain and supernatants of these DC cultures were harvested after 30 h). DC-derived supernatants were diluted 1:2 with fresh medium and placed into the lower wells of 24-well transwell plates with polycarbonate membrane filters (5 mm pore size; Corning, Tewksbury, MA). Mast cell progenitor cultures were set up as described (Collington et al. 52 ). Briefly, bone marrow cells were isolated and cultured for 4-5 days with 10 ng/ml IL-3 and 50 ng/ml SCF (kindly provided by Dr M. Gurish), and 5 Â 10 5 cells (in 100 ml, average cell size 10 mm) were placed into the upper chambers of the transwell plates. Migrated cells were collected after 2 h, stained for cell-type-specific marker molecules, and analyzed by flow cytometry. To quantify cell migration, CountBright Counting Beads (Invitrogen, Grand Island, NY) were used. mRNA expression analysis. Digital mRNA profiling was performed using multiplexed mRNA expression analysis applying the nCounter assay system (NanoString Technologies, Seattle, WA). Tissue was harvested and rapidly transferred into RNAlater solution (Ambion, Foster City, CA) and stored at À 80 1C. Tissue was homogenized in RLT Buffer (Qiagen, Valencia, CA ) with b-mercaptoethanol (Sigma Aldrich) using the GentleMACS Dissociator with GentleMACS M tubes (Miltenyi Biotec). Tissue lysates of small intestine, lungs, or purified RNA (100 ng) from DCs were hybridized with customized nCounter gene expression code sets and direct mRNA counts were determined by the nCounter Digital Analyzer System according to the manufacturer's protocol. mRNA counts were first normalized to internal positive and negative controls before normalization to five house-keeping genes (i.e., b-actin, HPRT-1, HSP90ab1, Shfm-1, and Tomm7). Data are presented as direct mRNA counts or as fold difference compared with control-treated samples.
Immunoblotting. Cells were lysed in RIPA buffer (Santa Cruz Biotechnologies, Dallas, TX) containing protease inhibitors (Complete, Roche, Indianapolis, IN) and 2 mM sodium orthovanadate. Samples were run on 10% SDS-PAGE gels, transferred to PVDF membranes (Pierce, Rockford, IL) and probed with following antibodies: anti-Syk and anti-phospho SYK, anti-ERK1/2 and antiphospho ERK1/2 (all from Cell Signaling Technology, Danvers, MA) followed by peroxidase-conjugated goat anti-rabbit or goat anti-mouse IgG. Peroxidase activity was detected using SuperSignal chemiluminescent substrate reagents (Pierce).
Microscopy. Frozen small intestinal tissue sections of IgER-TG mice were stained with PE-labeled mouse anti-human FceRI (Cra1; eBioscience) and Alexa Fluor 647labeled-anti mouse CD11c. Specificity of the staining was confirmed with appropriate isotype control antibodies and tissue from WT mice. Immunofluorescence histoche-mistry of human gastrointestinal tissue was performed as described using discarded tissue of a published cohort. 79 All microscopy was performed at the Harvard Digestive Disease Center Core Facility.
T-cell proliferation assays. DCs were isolated using CD11c MicroBeads (Miltenyi Biotec). Purity (490%) was assessed by FACS. To preload DCs with IgE, cells were cultured over night at 371C with NP-specific IgE (500 ng/ml). For T-cell isolation OT-II mice, the CD4 þ T Cell Isolation Kit II (Miltenyi Biotec) was used. Purified T cells were labeled using the CellTrace CFSE Cell Proliferation Kit (Molecular Probes, Eugene, OR). Prior to loading with antigen, unbound IgE was removed. In vitro assays were performed in the continuous presence of indicated antigen concentrations. Antigen presenting cells were plated with CFSE-labeled CD4 þ T cells at 1:2 to 1:4 ratios. For in vivo experiments, DCs (1-2 Â 10 6 cells/ml) were pulsed for 1 h with NP-OVA at concentrations of 0.05 mg/ml or 0.5 mg/ml. A total of 2.5 Â 10 5 DCs loaded with IgE and NP-OVA or equal DC numbers loaded only with NP-OVA were injected into opposite hind footpads of WT mice adoptively transferred with CFSE-labeled OT-II T cells. Popliteal lymph nodes were harvested after 72 h. For determining intracellular cytokine production, OT-II T cells were cultured with DCs at 1:5 ratio in 48-well plates with or without recombinant IL-4 (15 ng/ml, Peprotech) or LPS (1 mg/ml). On day 3 and 5, half of the culture medium was exchanged, and IL-4 and/or IL-2 (20 ng/ml) were added. On day 6 or 7, cells were restimulated with phorbol 12-myristate 13-acetate and ionomycin for 4 h. Brefeldin A was added for the last 3 h. For the generation of Th1 cells IL-12 (25 ng/ml) or CpG DNA (500 ng/ml) were added to the cocultures. For the iTreg assays, purified CD4 þ OT-II cells were depleted for CD25 þ cells using the CD25 MicroBead Kit (Miltenyi Biotec). T cells were cocultured in 96-well plates at 1:3 ratio with DCs in the presence of 5 ng/ ml TGF-b1. On day 3, half of the culture medium was exchanged, and fresh TGF-b1 and IL-2 (20 ng/ml) were added. On day 6, cells were analyzed by intracellular staining for Foxp3 and IL-10 using the Foxp3 staining Kit from eBiosciences. 
